Cover Image
市場調查報告書

Lee's Pharmaceutical Holdings Limited:產品平台分析

Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256080
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
Lee's Pharmaceutical Holdings Limited:產品平台分析 Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 72 Pages
簡介

Lee's Pharmaceutical Holdings Limited是總公司設立在香港的製藥企業,正在製造用於注射劑,局部用凝膠劑,少量的非口服劑,眼用軟膏的冷凍乾燥粉末。

本報告提供Lee's Pharmaceutical Holdings Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Lee's Pharmaceutical Holdings Limited的基本資料

  • Lee's Pharmaceutical Holdings Limited概要
  • 主要資訊
  • 企業資料

Lee's Pharmaceutical Holdings Limited:R&D概要

  • 主要的治療範圍

Lee's Pharmaceutical Holdings Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Lee's Pharmaceutical Holdings Limited:開發中產品概況

  • 後期階段產品開發中產品
    • 登記前的產品/聯合治療模式
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA登記階段的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Lee's Pharmaceutical Holdings Limited:藥物簡介

  • trazodone hydrochloride
  • prulifloxacin
  • gimatecan
  • istaroxime
  • RGN-259
  • rostafuroxin
  • ZK-001
  • ZK-003
  • ZK-010
  • ZK-011
  • ZK-012
  • ZK-014
  • ZK-016
  • (adapalene + clindamycin hydrochloride)
  • ZK-013
  • LQ-7
  • AK-12
  • STIA-1014
  • ZK-002
  • ZK-004
  • ZK-009
  • ZK-015
  • procarbazine hydrochloride

Lee's Pharmaceutical Holdings Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lee's Pharmaceutical Holdings Limited:最新的開發平台資訊

Lee's Pharmaceutical Holdings Limited:開發暫停中的計劃

Lee's Pharmaceutical Holdings Limited:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • gimatecan

Lee's Pharmaceutical Holdings Limited:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08142CDB

Summary

Global Markets Direct's, 'Lee's Pharmaceutical Holdings Limited - Product Pipeline Review - 2016', provides an overview of the Lee's Pharmaceutical Holdings Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lee's Pharmaceutical Holdings Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Lee's Pharmaceutical Holdings Limited
  • The report provides overview of Lee's Pharmaceutical Holdings Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Lee's Pharmaceutical Holdings Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Lee's Pharmaceutical Holdings Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Lee's Pharmaceutical Holdings Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lee's Pharmaceutical Holdings Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lee's Pharmaceutical Holdings Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lee's Pharmaceutical Holdings Limited Snapshot
    • Lee's Pharmaceutical Holdings Limited Overview
    • Key Facts
  • Lee's Pharmaceutical Holdings Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Lee's Pharmaceutical Holdings Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance
    • Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Lee's Pharmaceutical Holdings Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Lee's Pharmaceutical Holdings Limited - Drug Profiles
    • (adapalene + clindamycin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AK-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azilsartan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gimatecan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • istaroxime - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levobetaxolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levocarnitine propionate hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LQ-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazufloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • procarbazine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGN-259 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rostafuroxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STIA-1014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tecarfarin sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trazodone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZK-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lee's Pharmaceutical Holdings Limited - Pipeline Analysis
    • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Target
    • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration
    • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Molecule Type
    • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action
  • Lee's Pharmaceutical Holdings Limited - Dormant Projects
  • Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • betrixaban
      • ecallantide
      • gimatecan
      • NOV-002
      • NOV-205
      • prulifloxacin
      • RGN-259
  • Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lee's Pharmaceutical Holdings Limited, Key Facts
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Indication, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2016
  • Lee's Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2016
  • Lee's Pharmaceutical Holdings Limited - Combination Treatment Modalities in Pipeline, 2016
  • Lee's Pharmaceutical Holdings Limited - Partnered Products in Pipeline, 2016
  • Lee's Pharmaceutical Holdings Limited - Partnered Products/ Combination Treatment Modalities, 2016
  • Lee's Pharmaceutical Holdings Limited - Pre-Registration, 2016
  • Lee's Pharmaceutical Holdings Limited - Phase III, 2016
  • Lee's Pharmaceutical Holdings Limited - Phase II, 2016
  • Lee's Pharmaceutical Holdings Limited - Phase I, 2016
  • Lee's Pharmaceutical Holdings Limited - IND/CTA Filed, 2016
  • Lee's Pharmaceutical Holdings Limited - Preclinical, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Target, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Route of Administration, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Molecule Type, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Mechanism of Action, 2016
  • Lee's Pharmaceutical Holdings Limited - Dormant Developmental Projects,2016
  • Lee's Pharmaceutical Holdings Limited - Discontinued Pipeline Products, 2016
  • Lee's Pharmaceutical Holdings Limited, Subsidiaries

List of Figures

  • Lee's Pharmaceutical Holdings Limited - Pipeline by Top 10 Indication, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Stage of Development, 2016
  • Lee's Pharmaceutical Holdings Limited - Monotherapy Products in Pipeline, 2016
  • Lee's Pharmaceutical Holdings Limited - Partnered Products in Pipeline, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Top 10 Target, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Route of Administration, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline by Molecule Type, 2016
  • Lee's Pharmaceutical Holdings Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top